OncoMed Pharmaceuticals granted fourth RSPO-LGR pathway patent in US
The new patent, US patent No. 8,628,774, covers certain methods of treating cancer with antibodies that bind human leucine-rich repeat-containing G protein-coupled receptor (LGR) proteins and either disrupt
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.